Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
--Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem----Cash Runway into 2024--...